The overall goal of this Program Project is to identify the most potent biomarkers involved in the pathogenesis and progression of human breast cancer. This molecular fingerprint derived from an individual patient's tissue or tumor specimen would help clinicians distinguish women at highest risk for acquiring breast cancer, as well as those with breast cancer most in need of specific systemic therapies. Additionally, identification of these biomarkers should provide new targets for innovative therapeutic or treatment strategies. Building on accomplishments of the current Program Project, proposed individual projects will study: 91) integration of new and existing prognostic factor information into useful indexes to identify more accurately breast cancer patients at lowest and highest risk of recurrence, and to help predict responsiveness to specific therapies; (2) the role of estrogen receptor variants, many of them discovered here, as well as altered receptor expression, in progression of premalignant lesions and breast disease toward invasive cancer 94) a new gene on chromosome 14q apparently required for metastasis; and (5) the mechanism for the failed nuclear translocation of the BRCA1 protein which we have recently discovered. These projects will be supported by the San Antonio Breast tumor Bank and Data Network, containing many thousands of breast tumor specimens with associated clinical data and long-term follow-up, and also by core laboratories for histology/immunohistochemistry, tissue culture, and microdissection, along with an administrative core function. These highly interactive projects are designed to enhance our knowledge of how breast cells become malignant and invasive, and to use this knowledge to predict tumor behavior and probable treatment responses for the patient's benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030195-17A1
Application #
2386900
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-03-01
Project End
2002-07-31
Budget Start
1997-09-17
Budget End
1998-07-31
Support Year
17
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Pathiraja, Thushangi N; Shetty, Priya B; Jelinek, Jaroslav et al. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:4177-86
Heckman-Stoddard, B M; Vargo-Gogola, T; Herrick, M P et al. (2011) P190A RhoGAP is required for mammary gland development. Dev Biol 360:1-10

Showing the most recent 10 out of 260 publications